Tamsulosin Hydrochloride Capsule
Product Images NDC 71610-910

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Tamsulosin Hydrochloride (NDC 71610-910). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (71610 0910 30)

Tamsulosin Hydrochloride USP 0.4 mg capsules in a 30-capsule package. The label displays the NDC 71610-910-30 and storage instructions to keep between 20-25 degrees Celsius, protected from light and moisture. Manufactured by Alfen Spain, S.L., Barcelona, Spain, and packaged by Aphena Pharma, Cookeville, TN. RX only.*

FDA Label Image

Aphena (Aphena)

FDA Label Image

Figure 2b.jpg (Figure 2b)

A line graph displaying mean change over a 13-week treatment period for Tamsulosin hydrochloride capsules at 0.4 mg and 0.8 mg doses compared with placebo. The x-axis represents treatment duration in weeks, and the y-axis shows mean change. Data points include sample sizes for each time period, including last observation carried forward (LOCF) at week 13.*

FDA Label Image

Figure 3a.jpg (Figure 3a)

A line graph showing the mean change in mL/sec over the duration of treatment in weeks for Tamsulosin hydrochloride 0.4 mg, 0.8 mg, and placebo groups. The x-axis represents the weeks of treatment (0 to 13 weeks plus LOCF), while the y-axis shows mean change in mL/sec from 0 to 3. The graph includes plotted data points connected by lines for each group, indicating trends in treatment effect over time.*

FDA Label Image

Figure 3b.jpg (Figure 3b)

A line graph showing mean change in mL/sec over treatment duration in weeks. It compares three groups: 0.8 mg dose, 0.4 mg dose, and placebo, with data points for weeks 1, 2, 4, 7, 9, 13, and last observation carried forward (LOCF). The y-axis measures mean change, and the x-axis shows treatment duration in weeks.*

FDA Label Image

Figure1.jpg (Figure1)

A pharmacokinetic concentration-time curve showing plasma concentration (ng/mL) of Tamsulosin hydrochloride over 36 hours. The graph compares plasma levels after administration in fasted (dashed line) and fed (solid line) states, illustrating differences in absorption and concentration peak times.*

FDA Label Image

Figure2a. (Figure2a.jpg)

A line graph showing mean change over duration of treatment in weeks for Tamsulosin hydrochloride at 0.4 mg and 0.8 mg doses versus placebo. The y-axis represents mean change, and the x-axis the duration of treatment up to 13 weeks. Data points are marked for each group with corresponding sample sizes noted per time point, indicating greater improvement with the 0.8 mg dose.*

FDA Label Image

Str. (Str)

Chemical structure diagram of tamsulosin hydrochloride, showing the molecular arrangement including aromatic rings, an amine group, methoxy groups, and a hydrochloride component.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.